Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
FDA sends this letter dated 07/23 to Spectrum pharma on Zevalin marketing practices ->Full Letter here Link
Mr. Anil Hiteshi, RAC,
Vice President, Global Regulatory Affairs
157 Technology Drive
Irvine, CA 92618
RE: BLA #125019
ZEVALIN® (ibritumomab tiuxetan) Injection for Intravenous Use
Dear Mr. Hiteshi:
As part of its routine monitoring and surveillance program, the Office of Prescription Drug
Promotion (OPDP), of the U.S. Food and Drug Administration (FDA) has reviewed a
professional sales aid (0103058300) (sales aid) for ZEVALIN®
(ibritumomab tiuxetan) Injection for Intravenous Use (Zevalin) submitted by Spectrum Pharmaceuticals, Inc. (Spectrum) under cover of Form FDA 2253. This sales aid is false or misleading because it minimizes important risk information, overstates the efficacy of Zevalin, and omits material facts. Thus, the sales aid misbrands Zevalin in violation of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 352(a) & 321(n), and implementing regulation 21 CFR 1.21(a). Cf. 21 CFR 202.1(e)(5)(i), (iii); (e)(6)(i), (x), (xviii).
If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.